Literature DB >> 26171031

Pregnancy-induced hypertension caused by all-trans retinoic acid treatment in acute promyelocytic leukemia.

Kui Song1, Min Li2.   

Abstract

A 23-year-old pregnant female presented with fever and diarrhea during the sixth month of gestation. The patient was diagnosed with acute promyelocytic leukemia (APL) at 26 weeks gestation and was treated with all-trans retinoic acid (ATRA) at an initial dose of 45 mg/m2/day, which was reduced to 25 mg/m2/day 14 days later. The patient experienced chest distress, polypnea, hypertension, general dropsy and dysfunction of the kidneys and heart on day 3 of the treatment, which suggested pregnancy-induced hypertension. Intrauterine fetal demise was apparent on day 8. A cesarean delivery was performed, however, intrauterine fetal mortality had occurred. A favorable outcome was achieved for the patient following treatment, although hematological complete remission was slow. To the best of our knowledge, the present study is the first to describe an APL patient with pregnancy-induced hypertension following treatment with ATRA, and thus ATRA remains a suitable for therapy for APL during pregnancy.

Entities:  

Keywords:  acute promyelocytic leukemia; all-trans retinoic acid; pregnancy-induced hypertension

Year:  2015        PMID: 26171031      PMCID: PMC4487150          DOI: 10.3892/ol.2015.3190

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  11 in total

1.  Acute promyelocytic leukemia and pregnancy.

Authors:  A A Giagounidis; M W Beckmann; A S Giagounidis; M Aivado; T Emde; U Germing; T Riehs; A Heyll; C Aul
Journal:  Eur J Haematol       Date:  2000-04       Impact factor: 2.997

Review 2.  Angiotensin II receptor antagonist treatment during pregnancy.

Authors:  S Alwan; J E Polifka; J M Friedman
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2005-02

3.  Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.

Authors:  M S Tallman; J W Andersen; C A Schiffer; F R Appelbaum; J H Feusner; A Ogden; L Shepherd; J M Rowe; C François; R S Larson; P H Wiernik
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

4.  Acute promyelocytic leukemia: an unusual cause showing prolonged disseminated intravascular coagulation after placental abruption.

Authors:  Yukako Morimatsu; Shigeki Matsubara; Noriko Hirose; Akihide Ohkuchi; Akio Izumi; Katsutoshi Ozaki; Keiya Ozawa; Mitsuaki Suzuki
Journal:  Arch Gynecol Obstet       Date:  2007-08-23       Impact factor: 2.344

Review 5.  Maternal obesity and pregnancy.

Authors:  Hemant K Satpathy; Alfred Fleming; Donald Frey; Michael Barsoom; Chabi Satpathy; Jimmy Khandalavala
Journal:  Postgrad Med       Date:  2008-09-15       Impact factor: 3.840

6.  Acute promyelocytic leukemia: recent advances in diagnosis and management.

Authors:  Francesco Lo-Coco; Emanuele Ammatuna; Pau Montesinos; Miguel Angel Sanz
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

Review 7.  The expanding role of arsenic in acute promyelocytic leukemia.

Authors:  Martin S Tallman
Journal:  Semin Hematol       Date:  2008-07       Impact factor: 3.851

Review 8.  Treatment of acute promyelocytic leukemia in the very elderly: case report and review of the literature.

Authors:  Ronald L Sham; Martin S Tallman
Journal:  Leuk Res       Date:  2004-12       Impact factor: 3.156

9.  Successful treatment of acute promyelocytic leukaemia during pregnancy.

Authors:  D Carradice; N Austin; K Bayston; P S Ganly
Journal:  Clin Lab Haematol       Date:  2002-10

10.  Acute promyelocytic leukaemia presenting as postpartum haemorrhage.

Authors:  R J A Murrin; V Adjetey; P Harrison; A Warwick
Journal:  Clin Lab Haematol       Date:  2004-06
View more
  1 in total

1.  Acute Promyelocytic Leukemia during Pregnancy: A Systematic Review of the Literature.

Authors:  Andrea Santolaria; Alfredo Perales; Pau Montesinos; Miguel A Sanz
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.